Calliditas Therapeutics IPO Presentation Deck
Planned open-label extension and chronic dosing trials
Open-label extension trial:
For eligible patients who have completed treatment in Part A and Part B of NefigArd trial
Expected to commence in 4Q 2020 when first patient has completed both Part A and Part B of NefigArd trial
Open-label chronic dosing trial:
Expect to commence in 2021 to provide safety and efficacy data for chronic treatment with Nefecon
Leveraging existing sites and networks
Inclusion criteria expected to be similar to those used in NeflgArd trial
All patients enrolled will be on active treatment, starting with 16 mg once daily dose for 9 months of treatment
followed by a maintenance dose
- Duration of maintenance dose will be determined based on regulatory feedback
Enables additional data capture related to safety and maintenance treatment
.
calliditas
June 2020
20View entire presentation